Pharmaceutical Pricing at the Change of Millennia

Journal of Pharmaceutical Marketing and Management

Volumn 10, Issue 42038, 1996, Pages 109-120

  Kolassa, Mick ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7344252145     PISSN: 08837597     EISSN: 15408574     Source Type: Journal    
DOI: 10.3109/J058v10n02_07     Document Type: Article

References (32)

1. Grabowski H, Vernon J. A sensitivity analysis of expected profitability of pharmaceutical research and development. Manage Dec Econ 1992; 3 (1): 36 – 40.
2. Zelnio RN, Gagnon JP. The effects of price information on prescription drug product selection. Drug Intell Clin Pharm 1979; 13: 156 – 9.
3. Chukkapalli R, Kolassa EM, Ogilvey S, Hayman-Taylor T. The 15 year trend in prices at launch for outpatient prescription medications. Unpublished.
4. U.S. Senate. Special Committee on Aging. Prescription drug prices: are we getting our money's worth? Serial No. 101-F. Washington, DC, 1991
5. Pryor D. A prescription for high drug prices. Health Aff 1990; 9: 101 – 9.
6. Dranove D. Medicaid drug formulary restrictions. J Law Econ 1989 23: 143 – 62.
7. Curran JP. Strategic shifts in pricing policies. Pharm Exec 1986;6(Apr): 92 – 4.
8. Boston Consulting Group. The changing environment for U.S. pharmaceu-ticals. New York: Boston Consulting Group, April 1993.
9. Grabowski HG, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ 1992; 23: 331 – 50.
10. Bloom BS, Wierz DJ, Pauly MV. Cost and price of comparable branded and generic pharmaceuticals. JAMA 1986; 256: 2523 – 30.
11. EMS America. National Prescription Audit. October-December 1994. Plymouth Meeting, PA: IMS America.
12. Medispan Inc. Price Check-PC. December 1994. Indianapolis, IN: Medis-pan Inc.
13. Pathak DS, Klinger PA. Predictive factors in bid purchasing of antibiotics. Top Hosp Pharm Manage 1981; 1 (1): 17 – 28.
14. Taylor S, Kucukarslan S, Sherrin T. Evidence and response to the impact of the Medicaid Drug Rebate Program (OBRA) on hospital pharmacy: a progress re-port from central Ohio. Hosp Pharm 1991; 26: 621 – 5.
15. Palumbo FB, Schondelmeyer SW, Miller DW, Speedie SM. Battered bot-tom lines: the impact of eroding pharmaceutical discounts on health-care institu-tions. Am J Hosp Pharm 1992; 49: 1177 – 85.
16. Wilensky GR, Blumberg LJ, Neumann PJ. Chapter 4. Pharmaceuticals and decision-making in the United States: cost consciousness and the changing locus of control. In: van Eimeren W, Horisberger B, eds. Socioeconomic evaluation of drug therapy. Berlin, New York: Springer-Verlag, 1988: 32 – 45.
17. Wertheimer Al, Grinner SK. Overview of international pharmacy pricing. Pharmaco Economics 1992; 2: 449 – 55.
18. Anon. European price controls not sufficient to control drug spending without policies in place to control use. FDC Rep-Pinksheet 1994;(Jul 4): 7 – 9.
19. Brown RE, Luce BR. The value of pharmaceuticals: a study of selected conditions to measure the contribution of pharmaceuticals to health status. Wash-ington, DC: Battelle Medical Technology and Policy Research Center, March 1990.
20. Andersson F, McMenamin P. International price comparisons of pharma-ceuticals—a review of methodological issues. London and Washington, DC: Bat-telle Medical Technology and Policy Centre (MEDTAP), 1992.
21. U.S. General Accounting Office. Prescription drugs: companies typically charge more in the United States than in Canada. Report to the Chairman, House Subcommittee on Health and the Environment, Committee on Energy and Com-merce. GAO/HRD-920119. Washington, DC: September 1992.
22. Soumerai SB, Ross-Degnan D. Experience of state drug benefit programs. Health Aff 1990; 9: 36 – 54.
23. Goodman JC, Dolan EG. Economics of public policy. St. Paul, MN: West Publishing Company, 1985.
24. Kozma CM, Reeder CE, Lingle EW. Expanding Medicaid drug formulary coverage: effects on utilization of related services. Med Care 1990; 28: 963 – 76.
25. Reutzel Ti. The nature and consequences of policies intended to contain costs in outpatient drug insurance programs. Clin Ther 1993; 15: 752 – 64.
26. Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care 1985; 23: 872 – 80.
27. Hefner DL. Cost effectiveness of a restrictive drug formulary. Washington, DC: National Pharmaceutical Council, 1980.
28. Moore WI, Newman RI. U.S. Medicaid drug formularies: do they work? Pharmaco Econornics 1992; 1 \(Suppl 1): 28 – 31.
29. Smith MC, Simmons S. A study of the effects of formulary limitations in Medicaid programs. Adrnin Policy J 1982; 2: 169 – 98.
30. Rucker TD, Morse ML. The Medicaid drug program in Louisiana: critique of the Hefner-Pracon Study. Am J Hosp Pharm 1980; 37: 1350 – 3.
31. Nelson AA, Reeder CE, Dickson WM. The effect of a Medicaid drug co-payment program on the utilization of prescription services. Med Care 1984; 22: 724 – 36.
32. Soumerai SE, Avom I, Ross-Degnan D, Gortrnaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med 1987; 317: 550 – 6.